Loading...
Loading...
SABS| Name | Value |
|---|---|
| Revenues | 0.3M |
| Cost of Revenue | 0.9M |
| Gross Profit | -0.6M |
| Operating Expense | 18.2M |
| Operating I/L | -18.9M |
| Other Income/Expense | -4.0M |
| Interest Income | 0.5M |
| Pretax | -22.9M |
| Income Tax Expense | -0.0M |
| Net Income/Loss | -22.9M |
SAB Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company specializing in developing immunotherapies based on human antibodies. Using advanced genetic engineering, the company has created transchromosomic bovine herds that produce fully human antibodies targeting infectious diseases like COVID-19 and influenza, as well as immune and autoimmune disorders such as type 1 diabetes, organ transplantation, and cancer. SAB Biotherapeutics' DiversitAb immunotherapy platform enables the production of fully-human polyclonal antibodies without human donors. Its lead product candidates include SAB-185, a fully-human polyclonal antibody in Phase III clinical trial for COVID-19, and SAB-176, a candidate for severe influenza treatment or prevention.
